CA2034569A1 - Oral pharmaceutical forms of pimobendan - Google Patents

Oral pharmaceutical forms of pimobendan

Info

Publication number
CA2034569A1
CA2034569A1 CA002034569A CA2034569A CA2034569A1 CA 2034569 A1 CA2034569 A1 CA 2034569A1 CA 002034569 A CA002034569 A CA 002034569A CA 2034569 A CA2034569 A CA 2034569A CA 2034569 A1 CA2034569 A1 CA 2034569A1
Authority
CA
Canada
Prior art keywords
pimobendan
oral pharmaceutical
pharmaceutical forms
fluctuations
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002034569A
Other languages
French (fr)
Other versions
CA2034569C (en
Inventor
Peter Gruber
Willy Roth
Gottfried Schepky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of CA2034569A1 publication Critical patent/CA2034569A1/en
Application granted granted Critical
Publication of CA2034569C publication Critical patent/CA2034569C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Constant, satisfactory resorption of pimobendan is ensured even when there are major pH fluctuations in the gastrointestinal tract, when it is formulated for oral administration together with citric acid.
CA002034569A 1990-01-20 1991-01-18 Oral pharmaceutical forms of pimobendan Expired - Lifetime CA2034569C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4001622A DE4001622A1 (en) 1990-01-20 1990-01-20 ORAL DRUGS OF PIMOBENDAN
DEP4001622.6 1990-01-20

Publications (2)

Publication Number Publication Date
CA2034569A1 true CA2034569A1 (en) 1991-07-21
CA2034569C CA2034569C (en) 2002-03-19

Family

ID=6398467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002034569A Expired - Lifetime CA2034569C (en) 1990-01-20 1991-01-18 Oral pharmaceutical forms of pimobendan

Country Status (18)

Country Link
EP (1) EP0439030B1 (en)
JP (1) JP2608183B2 (en)
KR (1) KR0163056B1 (en)
AT (1) ATE87481T1 (en)
AU (1) AU630536B2 (en)
CA (1) CA2034569C (en)
DE (2) DE4001622A1 (en)
DK (1) DK0439030T3 (en)
ES (1) ES2054379T3 (en)
FI (1) FI96274C (en)
HK (1) HK175796A (en)
HU (1) HU207948B (en)
IE (1) IE64659B1 (en)
IL (1) IL96995A (en)
NO (1) NO176305C (en)
NZ (1) NZ236834A (en)
PT (1) PT96506B (en)
ZA (1) ZA91372B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8664252B2 (en) 2008-11-25 2014-03-04 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US8846679B2 (en) 2004-03-08 2014-09-30 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical composition comprising pimobendan
US9107952B2 (en) 2006-11-07 2015-08-18 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US9889148B2 (en) 2004-03-25 2018-02-13 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US10071162B2 (en) 2013-07-19 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10117869B2 (en) 2004-03-25 2018-11-06 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
US10172804B2 (en) 2013-12-04 2019-01-08 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753904B1 (en) * 1996-10-01 1998-10-30 Gattefosse Ets Sa PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE SUBSTANCE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
WO2005123040A1 (en) * 2004-06-22 2005-12-29 Shionogi & Co., Ltd. Tablet rapidly disintegrating in mouth
JP4572293B2 (en) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 Pimobendan oral dosage formulation
JP4572296B2 (en) * 2004-07-21 2010-11-04 トーアエイヨー株式会社 Pimobendan oral dosage formulation
JP2006028130A (en) * 2004-07-21 2006-02-02 Toa Eiyo Ltd Pimopendan preparation for oral administration
WO2007035874A1 (en) * 2005-09-21 2007-03-29 Bristol-Myers Squibb Company Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
JP4572300B2 (en) * 2006-01-19 2010-11-04 トーアエイヨー株式会社 Pimobendan oral dosage formulation
PE20081482A1 (en) * 2006-12-20 2008-12-23 Novartis Ag GELATINE CAPSULES CONTAINING AN ACID
FR2934156B1 (en) * 2008-07-23 2010-09-24 Virbac ORAL ADMINISTRATION MEDICAMENT IN SOLID FORM
WO2010055119A2 (en) * 2008-11-17 2010-05-20 Novartis Ag Pharmaceutical composition comprising pimobendan
NL1037569C2 (en) 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
JPWO2011081118A1 (en) * 2009-12-29 2013-05-13 興和株式会社 Pharmaceutical composition for oral administration
EP2520299A1 (en) * 2009-12-29 2012-11-07 Kowa Co., Ltd. Solid pharmaceutical composition for oral administration
CN106729723A (en) * 2016-11-21 2017-05-31 青岛农业大学 A kind of pharmaceutical composition containing UD-CG115BS.acardi and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES482789A0 (en) * 1978-08-25 1980-12-01 Thomae Gmbh Dr K PROCEDURE FOR THE PREPARATION OF NEW BENZHIMIDAZOLES REPLACED IN POSITION 5 OR 6 WITH A PYRIDAZINONE RING
DE2837161A1 (en) * 1978-08-25 1980-03-06 Thomae Gmbh Dr K 5-Alkyl:pyridazinyl substd. benzimidazole derivs. - useful as cardiovascular agents, antivirals, interferon inducers and ulcer inhibitors
JPS56110612A (en) * 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Readily disintegrable and absorbable compression molded article of slightly soluble drug
JPS60163823A (en) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd Oral administration pharmaceutical
DE3776269D1 (en) * 1986-11-03 1992-03-05 Schering Corp LABETALOL TABLET WITH DELAYED DELIVERY OF ACTIVE SUBSTANCES.
DE3728244A1 (en) * 1987-08-25 1989-03-09 Thomae Gmbh Dr K Novel (-)-benzimidazoles, their preparation and medicaments containing these compounds
EP0306846A3 (en) * 1987-09-11 1990-05-02 Dr. Karl Thomae GmbH Synergistic combination comprising a phosphodiesterase inhibitor and a thromboxane-a2 antagonist, and its use or preparation
DE3805635A1 (en) * 1988-02-24 1989-09-07 Thomae Gmbh Dr K USE OF BENZIMIDAZOLES FOR THE MANUFACTURE OF A MEDICAMENT WITH ANTI-MIXIC EFFECTS ON THE HEART AND ITS COMBINATIONS WITH SS-BLOCKERS OR BRADYCARDICA
JPH01258621A (en) * 1988-04-06 1989-10-16 Fujimoto Seiyaku Kk Dilazep tablet with regulated absorption
JPH023609A (en) * 1988-06-21 1990-01-09 Fujimoto Seiyaku Kk Long-acting drug preparation containing nicardipine hydrochloride as active component

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846679B2 (en) 2004-03-08 2014-09-30 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical composition comprising pimobendan
US8846680B2 (en) 2004-03-08 2014-09-30 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical composition comprising pimobendan
US8859554B2 (en) 2004-03-08 2014-10-14 Boehringer Ingelheim Vetmedica Gmbh Packaging assembly for pharmaceutical composition including pimobendan
US10117869B2 (en) 2004-03-25 2018-11-06 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
US11413285B2 (en) 2004-03-25 2022-08-16 Boehringer Ingelheim Vetmedica Gmbh PDE III inhibitors for treatment of asymptomatic heart failure
US10537588B2 (en) 2004-03-25 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US9889148B2 (en) 2004-03-25 2018-02-13 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
US9107952B2 (en) 2006-11-07 2015-08-18 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US9616134B2 (en) 2006-11-07 2017-04-11 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US10639305B2 (en) 2006-11-07 2020-05-05 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising pimobendan
US8664252B2 (en) 2008-11-25 2014-03-04 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US10071162B2 (en) 2013-07-19 2018-09-11 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US11185590B2 (en) 2013-07-19 2021-11-30 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
US10172804B2 (en) 2013-12-04 2019-01-08 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10653633B2 (en) 2013-12-04 2020-05-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10874620B2 (en) 2013-12-04 2020-12-29 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US11298325B2 (en) 2013-12-04 2022-04-12 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Also Published As

Publication number Publication date
IL96995A0 (en) 1992-03-29
HU207948B (en) 1993-07-28
NO176305C (en) 1995-03-15
NZ236834A (en) 1995-10-26
HUT56494A (en) 1991-09-30
AU630536B2 (en) 1992-10-29
EP0439030A2 (en) 1991-07-31
CA2034569C (en) 2002-03-19
ZA91372B (en) 1992-09-30
JP2608183B2 (en) 1997-05-07
HK175796A (en) 1996-09-27
EP0439030B1 (en) 1993-03-31
JPH04210919A (en) 1992-08-03
PT96506A (en) 1991-10-15
EP0439030A3 (en) 1991-10-16
IE64659B1 (en) 1995-08-23
NO910213D0 (en) 1991-01-18
FI96274C (en) 1996-06-10
DE59100067D1 (en) 1993-05-06
ES2054379T3 (en) 1994-08-01
PT96506B (en) 1998-06-30
IL96995A (en) 1994-11-11
DE4001622A1 (en) 1991-07-25
FI910263A0 (en) 1991-01-18
KR910014120A (en) 1991-08-31
IE910165A1 (en) 1991-07-31
FI910263A (en) 1991-07-21
ATE87481T1 (en) 1993-04-15
NO910213L (en) 1991-07-22
HU910177D0 (en) 1991-08-28
NO176305B (en) 1994-12-05
AU6945491A (en) 1991-07-25
DK0439030T3 (en) 1993-08-16
KR0163056B1 (en) 1998-12-01
FI96274B (en) 1996-02-29

Similar Documents

Publication Publication Date Title
CA2034569A1 (en) Oral pharmaceutical forms of pimobendan
CA2194564A1 (en) Aqueous Risperidone Formulations
CA2005986A1 (en) Benzimidazole derivative with gastric acid inhibitory effect and process for its preparation
ITBO910024A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLICANS ABSORBABLE ORALLY.
CA2219991A1 (en) Taste masking pharmaceutical composition for oral administration
WO1997045091A3 (en) Sustained release oxycodone formulations with no fed/fast effect
CA2310585A1 (en) Novel administration form comprising an acid-labile active compound
CA2219818A1 (en) Novel compounds, the preparation and use thereof
YU17700A (en) Oral copositions of levosimendan
IL101771A0 (en) Carboxylic acid derivatives,their manufacture and pharmaceutical compositions containing them
CA2507743A1 (en) Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
AU4059485A (en) Substituted benzopyrans
CA2281054A1 (en) Combination of zinc ions and vitamin c and method of making
ITMI911880A1 (en) METHOD FOR THE PREPARATION OF ORAL PHARMACEUTICAL FORMS WITH EXTENDED RELEASE CONTAINING ACTIVE SUBSTANCES SOLUBILITY DEPENDENT ON THE PH VALUE.
CA2168193A1 (en) Aryalkyl-thiadiazinones
EP0331092A3 (en) Alpha-amino-carboxylic-acid derivatives, their preparation and use
AU563822B2 (en) Pharmaceutical composition of piroxicam and 5'-guanylic acid or n-acetyl-l-methionine
ZA967537B (en) Novel carboxylic acid derivatives, their preparation and use.
IE813100L (en) Naphthyridine derivatives
NO913644D0 (en) PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE AMINO ACID DERIVATIVES.
CA2101548A1 (en) Acylamino-alkylidenhydroxy-bisphosphonic acids useful in the therapy of osteoarticular diseases
ITTO960094V0 (en) INFUSION KIT, ESPECIALLY FOR THE PARENTAL ADMINISTRATION OF THIOCTIC ACID.
ZA9210022B (en) Pyridylthiazolidinecarboxylic acid amide derivatives, their preparation and their therapeutic uses.
AU1845992A (en) Use of 9, 12, 15-octadecatriene-6-ynoic acid
TH12247EX (en) Correction tab

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry